MW Davis - US Patent 20,110,213,037, 2011 - freepatentsonline.com ... As a result of this genetic variation, about half of African-American subjects and 70-90% of Caucasian subjects do not express CYP3A5, while expression is more common in other ethnic groups. ... This method comprises the concomitant dosing of the patient with a sufficient ... Cached
MW Davis - US Patent 7,935,731, 2011 - Google Patents ... As a result of this genetic variation, about half of African-American subjects and 70 ... amount for the prophylactic treatment of gout flares in the absence of concomitant clarithromycin or ... In another embodiment, a method of using colchicine for prophylactic treatment of gout flares in ... Related articles - All 4 versions
A Rahnama, R Munns, K Poustini… - Journal of experimental …, 2011 - Soc Experiment Biol ... The method could also be useful to select for tolerance of toxic compounds such as boron or ... This phenotype of shorter axile roots with a concomitant increase in branch roots suggests that differentiation of ... Genotypic variation and possible mechanisms of salt tolerance in roots. ... Cited by 1 - Related articles - All 4 versions
MW Davis - US Patent 20,110,190,397, 2011 - freepatentsonline.com ... In a variation of this example, the initial treatment day in, a second colchicine dosing regimen that lasts for more than one day, has one more dose administered than are administered each subsequent day. ... The method entails the concomitant administration of a P-gp ... Cached
MW Davis - US Patent 7,915,269, 2011 - Google Patents ... another aspect, a method of using colchicine comprises increasing the blood plasma levels of colchicine in a indi- 5 vidual being administered doses of about 0.6 mg or less of colchicine to treat a colchicine-treatable condition, said method comprising the concomitant dosing of ... Related articles - All 4 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
